用于研究患者特异性肿瘤演变的乳腺癌患者衍生器官组织。

IF 5.3 2区 医学 Q1 ONCOLOGY Cancer Cell International Pub Date : 2024-06-27 DOI:10.1186/s12935-024-03375-5
Serena Mazzucchelli, Lorena Signati, Letizia Messa, Alma Franceschini, Arianna Bonizzi, Lorenzo Castagnoli, Patrizia Gasparini, Clarissa Consolandi, Eleonora Mangano, Paride Pelucchi, Ingrid Cifola, Tania Camboni, Marco Severgnini, Laura Villani, Barbara Tagliaferri, Stephana Carelli, Serenella M Pupa, Cristina Cereda, Fabio Corsi
{"title":"用于研究患者特异性肿瘤演变的乳腺癌患者衍生器官组织。","authors":"Serena Mazzucchelli, Lorena Signati, Letizia Messa, Alma Franceschini, Arianna Bonizzi, Lorenzo Castagnoli, Patrizia Gasparini, Clarissa Consolandi, Eleonora Mangano, Paride Pelucchi, Ingrid Cifola, Tania Camboni, Marco Severgnini, Laura Villani, Barbara Tagliaferri, Stephana Carelli, Serenella M Pupa, Cristina Cereda, Fabio Corsi","doi":"10.1186/s12935-024-03375-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.</p><p><strong>Methods: </strong>PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.</p><p><strong>Results: </strong>Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they showed typical mammary gland organization, confirming their reliability as a personalized in vitro model. Compared with O-PRE, O-POST had a greater proliferation rate with a significant increase in the Ki67 proliferation index. Moreover O-POST exhibited a more stem-like and aggressive phenotype, with increases in the CD24<sup>low</sup>/CD44<sup>low</sup> and EPCAM<sup>low</sup>/CD49f<sup>high</sup> cell populations characterized by increased tumour initiation potential and multipotency and metastatic potential in invasive lobular carcinoma. Analysis of ErbB receptor expression indicated a decrease in HER-2 expression coupled with an increase in EGFR expression in O-POST. In this context, deregulation of the PI3K/Akt signalling pathway was assessed by transcriptomic analysis, confirming the altered transcriptional profile. Finally, transcriptomic single-cell analysis identified 11 cell type clusters, highlighting the selection of the luminal component and the decrease in the number of Epithelial-mesenchymal transition cell types in O-POST.</p><p><strong>Conclusion: </strong>Neoadjuvant treatment contributed to the enrichment of cell populations with luminal phenotypes that were more resistant to chemotherapy in O-POST. PDOs represent an excellent 3D cell model for assessing disease evolution.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210105/pdf/","citationCount":"0","resultStr":"{\"title\":\"Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.\",\"authors\":\"Serena Mazzucchelli, Lorena Signati, Letizia Messa, Alma Franceschini, Arianna Bonizzi, Lorenzo Castagnoli, Patrizia Gasparini, Clarissa Consolandi, Eleonora Mangano, Paride Pelucchi, Ingrid Cifola, Tania Camboni, Marco Severgnini, Laura Villani, Barbara Tagliaferri, Stephana Carelli, Serenella M Pupa, Cristina Cereda, Fabio Corsi\",\"doi\":\"10.1186/s12935-024-03375-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.</p><p><strong>Methods: </strong>PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.</p><p><strong>Results: </strong>Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they showed typical mammary gland organization, confirming their reliability as a personalized in vitro model. Compared with O-PRE, O-POST had a greater proliferation rate with a significant increase in the Ki67 proliferation index. Moreover O-POST exhibited a more stem-like and aggressive phenotype, with increases in the CD24<sup>low</sup>/CD44<sup>low</sup> and EPCAM<sup>low</sup>/CD49f<sup>high</sup> cell populations characterized by increased tumour initiation potential and multipotency and metastatic potential in invasive lobular carcinoma. Analysis of ErbB receptor expression indicated a decrease in HER-2 expression coupled with an increase in EGFR expression in O-POST. In this context, deregulation of the PI3K/Akt signalling pathway was assessed by transcriptomic analysis, confirming the altered transcriptional profile. Finally, transcriptomic single-cell analysis identified 11 cell type clusters, highlighting the selection of the luminal component and the decrease in the number of Epithelial-mesenchymal transition cell types in O-POST.</p><p><strong>Conclusion: </strong>Neoadjuvant treatment contributed to the enrichment of cell populations with luminal phenotypes that were more resistant to chemotherapy in O-POST. PDOs represent an excellent 3D cell model for assessing disease evolution.</p>\",\"PeriodicalId\":9385,\"journal\":{\"name\":\"Cancer Cell International\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2024-06-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11210105/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Cell International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12935-024-03375-5\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12935-024-03375-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:通过对一名被诊断为乳腺癌(BC)的69岁妇女的病例研究,建立了一个可靠的临床前患者来源器官组织(PDOs)模型,以研究新辅助化疗和手术前后的肿瘤演变情况。这些结果是通过从治疗前(O-PRE)和治疗后(O-POST)采集的组织中培养 PDOs 得出的:方法:通过组织学、免疫组化(IHC)、透射电子显微镜(TEM)、扫描电子显微镜(SEM)、共聚焦显微镜、流式细胞术、实时 PCR、大量 RNA-seq、单细胞 RNA 测序(scRNA-seq)和药物筛选对 PDO 培养物进行鉴定:结果:两种PDO培养物都再现了原始组织的组织学和分子特征,并表现出典型的乳腺组织,证实了其作为个性化体外模型的可靠性。与O-PRE相比,O-POST的增殖率更高,Ki67增殖指数显著增加。此外,O-POST 表现出更多的干细胞样和侵袭性表型,CD24-低/CD44-低和 EPCAM-低/CD49f-高细胞群增加,其特点是在浸润性小叶癌中肿瘤启动潜能、多能性和转移潜能增加。对 ErbB 受体表达的分析表明,在 O-POST 中,HER-2 表达减少,而 EGFR 表达增加。在这种情况下,通过转录组分析评估了 PI3K/Akt 信号通路的失调,证实了转录谱的改变。最后,转录组单细胞分析确定了11个细胞类型群,突出显示了O-POST中腔内成分的选择和上皮-间质转化细胞类型数量的减少:结论:新辅助治疗促使具有管腔表型的细胞群在O-POST中富集,这些细胞群对化疗更具抵抗力。PDO是评估疾病演变的绝佳三维细胞模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Breast cancer patient-derived organoids for the investigation of patient-specific tumour evolution.

Background: A reliable preclinical model of patient-derived organoids (PDOs) was developed in a case study of a 69-year-old woman diagnosed with breast cancer (BC) to investigate the tumour evolution before and after neoadjuvant chemotherapy and surgery. The results were achieved due to the development of PDOs from tissues collected before (O-PRE) and after (O-POST) treatment.

Methods: PDO cultures were characterized by histology, immunohistochemistry (IHC), transmission electron microscopy (TEM), scanning electron microscopy (SEM), confocal microscopy, flow cytometry, real-time PCR, bulk RNA-seq, single-cell RNA sequencing (scRNA-seq) and drug screening.

Results: Both PDO cultures recapitulated the histological and molecular profiles of the original tissues, and they showed typical mammary gland organization, confirming their reliability as a personalized in vitro model. Compared with O-PRE, O-POST had a greater proliferation rate with a significant increase in the Ki67 proliferation index. Moreover O-POST exhibited a more stem-like and aggressive phenotype, with increases in the CD24low/CD44low and EPCAMlow/CD49fhigh cell populations characterized by increased tumour initiation potential and multipotency and metastatic potential in invasive lobular carcinoma. Analysis of ErbB receptor expression indicated a decrease in HER-2 expression coupled with an increase in EGFR expression in O-POST. In this context, deregulation of the PI3K/Akt signalling pathway was assessed by transcriptomic analysis, confirming the altered transcriptional profile. Finally, transcriptomic single-cell analysis identified 11 cell type clusters, highlighting the selection of the luminal component and the decrease in the number of Epithelial-mesenchymal transition cell types in O-POST.

Conclusion: Neoadjuvant treatment contributed to the enrichment of cell populations with luminal phenotypes that were more resistant to chemotherapy in O-POST. PDOs represent an excellent 3D cell model for assessing disease evolution.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.90
自引率
1.70%
发文量
360
审稿时长
1 months
期刊介绍: Cancer Cell International publishes articles on all aspects of cancer cell biology, originating largely from, but not limited to, work using cell culture techniques. The journal focuses on novel cancer studies reporting data from biological experiments performed on cells grown in vitro, in two- or three-dimensional systems, and/or in vivo (animal experiments). These types of experiments have provided crucial data in many fields, from cell proliferation and transformation, to epithelial-mesenchymal interaction, to apoptosis, and host immune response to tumors. Cancer Cell International also considers articles that focus on novel technologies or novel pathways in molecular analysis and on epidemiological studies that may affect patient care, as well as articles reporting translational cancer research studies where in vitro discoveries are bridged to the clinic. As such, the journal is interested in laboratory and animal studies reporting on novel biomarkers of tumor progression and response to therapy and on their applicability to human cancers.
期刊最新文献
Life history dynamics of evolving tumors: insights into task specialization, trade-offs, and tumor heterogeneity. Exploiting acquired vulnerability to develop novel treatments for cholangiocarcinoma. Systematic multiomics analysis and in vitro experiments suggest that ITGA5 could serve as a promising therapeutic target for ccRCC. The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis. Exosome therapeutics for non-small cell lung cancer tumorigenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1